This is a type of sarcoma that starts in immature blood cells called myeloid cells. It often happens with leukemia.
Every report comes from a Lived member, sent anonymously.
Have you tried Cytarabine for Myeloid Sarcoma?
Myeloid sarcoma is a rare cancer in which immature blood-forming cells, called myeloid blasts, collect into a solid mass outside the bone marrow. These are the same abnormal cells that cause acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow. For that reason, doctors regard myeloid sarcoma as a form of AML, even when it first appears as a single lump and blood tests look normal. The mass can develop almost anywhere in the body. Common sites include the skin, soft tissues, lymph nodes, bone, the digestive tract, the breast and the reproductive organs; the brain and spinal canal are involved less often. What a person notices depends on where it grows and how large it becomes: a firm lump, raised skin nodules, pain or swelling, or problems caused by pressure on a nearby organ or nerve. Older names for the condition include chloroma and granulocytic sarcoma.
Myeloid sarcoma can appear at different points in the course of a blood cancer. It may be found at the same time as AML, months before any leukemia can be detected in the bone marrow, or as the first sign that AML has returned after treatment, including after a stem cell transplant. It can also arise from related bone marrow disorders: myelodysplastic syndromes, in which the marrow makes abnormal and poorly working blood cells, and myeloproliferative neoplasms, in which the marrow overproduces blood cells. In chronic myeloid leukemia, a myeloid sarcoma signals that the disease has progressed to its advanced blast phase. The factors linked with myeloid sarcoma are broadly the same as those for AML, including certain workplace and environmental exposures, lifestyle factors and genetic factors. In adults it is most often diagnosed between about 40 and 70 and is somewhat more common in men. Researchers do not yet fully understand why leukemia cells leave the marrow and settle in other tissues, although certain chromosome and gene changes inside the leukemia cells are seen more often when they do.
A biopsy of the mass is essential. Under the microscope, myeloid sarcoma can resemble other cancers, most often lymphoma, and it has been misdiagnosed in a substantial share of cases, particularly when the person has no known leukemia. A pathologist confirms the diagnosis by staining the tissue for proteins that mark myeloid cells and by testing the tumor's chromosomes and genes. Because myeloid sarcoma is a form of AML, the evaluation also includes blood tests and a bone marrow biopsy to see whether leukemia is present in the marrow as well. Genetic results from the tumor and the marrow help estimate risk and can identify changes that targeted medicines act on; the two samples do not always carry the same changes. Imaging maps how many sites are involved and later helps judge response to treatment. A PET/CT scan, which pairs a CT scan with positron emission tomography (PET), a scan that highlights metabolically active cancer, is useful for finding lesions throughout the body, and MRI is used for the brain, spine, eyes and bones.
Because myeloid sarcoma behaves like AML, the main treatment is usually the same whole-body therapy used for AML, started soon after diagnosis even when only one mass is found. Treating the lump alone is generally not enough: most people whose sarcoma appears without leukemia in the marrow go on to develop it there, typically within about 4 to 12 months. There are no large trials devoted to myeloid sarcoma, so plans follow AML principles and are tailored to the leukemia's genetic features, whether the disease is new or a relapse, and the person's age, fitness and other health conditions. For people who can tolerate it, this usually means intensive chemotherapy. For adults 75 or older, or those with health problems that rule out intensive treatment, a common AML option combines venetoclax (Venclexta), a pill that blocks a protein leukemia cells rely on to survive, with azacitidine or decitabine, injected medicines that alter how genes in leukemia cells are switched on and off. In myeloid sarcoma, responses to this combination appear more modest than in AML without a mass. When the leukemia carries changes in specific genes (known by short names such as FLT3, IDH1, IDH2 and NPM1), medicines that target those changes may be added. An allogeneic stem cell transplant, which replaces a person's blood-forming system with cells from a donor, is considered for eligible people on the same grounds as in AML, particularly when the disease is high risk. Radiation therapy can shrink a mass quickly when it presses on a vital structure such as the spinal cord, when it responds poorly to chemotherapy, or when the sarcoma returns after a transplant. Surgery has a limited role, mainly to obtain tissue for diagnosis.
Treatment follows the pattern of AML care: an initial phase aimed at clearing all detectable disease (remission), then further treatment to keep it from returning, which may include a transplant. Because the evidence for this rare condition comes from relatively small studies, care is guided by a hematologist-oncologist (a blood cancer specialist) who weighs the person's own disease features rather than a single standard protocol. The outlook varies widely. Large studies suggest that, overall, people with myeloid sarcoma do about as well as people with AML that has no mass, so the leukemia's genetic features, the person's age and fitness, and whether the disease is new or a relapse matter more than the mass itself. A history of myelodysplastic syndrome or a myeloproliferative neoplasm is linked with poorer results. It remains a serious cancer: in a US registry study of cases diagnosed from 2000 to 2016, about 39 percent of people were alive five years later, after accounting for deaths expected in the general population of the same age. Those figures predate some newer treatments. After treatment, follow-up includes blood counts, bone marrow tests and sometimes repeat imaging, because the disease can return in the marrow or as a new mass elsewhere in the body, including after a transplant.
See a doctor about a lump, skin nodules or swelling that persists or grows without a clear cause. Anyone who has had AML or another bone marrow disorder should tell their care team promptly about a new mass, since it can be the first sign the disease has returned. New back pain together with weakness or numbness in the legs, or loss of bladder or bowel control, can mean a mass is pressing on the spinal cord. That needs emergency evaluation, because prompt treatment helps protect nerve function.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Myeloid Sarcoma is like, what's helped you, or ask the community a question.